Clinical trials: HIV Reservoir
HIV Infections
Cannabinoids in PLWHIV on Effective ART
The purpose of this pilot study is to assess feasibility and to examine whether oral cannabinoids (capsules containing either Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) combined or CBD alone) are safe and well-tolerated…
- Trial name
- NCT03550352
- Testing
- TN-TC11M2 oral capsules (THC 2.5 mg/CBD 2.5 mg), TN-C200M2 oral capsules (CBD 200 mg)
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
HIV-1 Infection
A Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV Reservoirs
This is a phase II proof-of-concept trial study to assess the safety and efficacy of UB-421 monotherapy plus chidamide in changing the latent HIV reservoir among ART-treated HIV-1 adults with stably viral suppression who undergo…
- Trial name
- NCT05056974
- Testing
- UB-421, chidamide
- Where
- Taiwan
- Volunteers
- 11 people
- Sponsor
- United BioPharma
HIV Infection
Modulating the Impact of Critical Events in Early HIV Infection: Effect of ART Initiation and Alcohol Use
The overall objective is to determine the influence of timing of ART initiation and alcohol consumption on HIV disease course. ART initiation immediately after HIV infection largely results in smaller HIV reservoir and lower…
- Trial name
- MERLIN (NCT02744040)
- Testing
- ART initiation at time of HIV diagnosis, ART at 24 weeks
- Where
- Peru
- Volunteers
- 151 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
HIV-1 Infection
Effects of Dolutegravir Based Regimen on HIV-1 Reservoir and Immune Activation
We aim at comparing markers of HIV reservoir, monocyte function and immune activation between antiretroviral therapy (ART)-naïve (chronic infection or primary infection), ART-controlled or ART-failing HIV infected adults…
- Trial name
- NCT02557997
- Testing
- Blood tube bottom analyses
- Where
- France
- Volunteers
- 202 people
- Sponsor
- University Hospital, Strasbourg, France
Hiv
Early Administration of Romidepsin and 3BNC117 in Treatment-naïve HIV Patients Starting ART
To evaluate the effect of early viral reactivation by latency reversing agents (LRA) and/or administration of potent broadly neutralizing antibodies (bNAb) on the size of the latent HIV-1 reservoir in treatment naïve HIV-1…
- Trial name
- eCLEAR (NCT03041012)
- Testing
- Romidepsin, 3BNC117, Antiretrovirals
- Where
- 7 sites in Denmark, United Kingdom
- Volunteers
- 60 people
- Sponsor
- Aarhus University Hospital
HIV (Human Immunodeficiency Virus)
A Clinical Study Evaluating the Safety, Tolerability, and Effect on HIV Reservoir of Ibalizumab Combined With Chidamide (a Histone Deacetylase Inhibitor) in People Living With HIV
HIV viral reservoirs represent the major barrier to curing AIDS, and effectively reducing viral reservoirs in people living with HIV through different strategies has become a research priority in the HIV field.
- Trial name
- NCT07635992
- Testing
- Ibalizumab Combined with Chidamide
- Volunteers
- 18 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
HIV Infections
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
This study investigates the use of VH3810109 with or without FTR to reduce the size and activity of the HIV viral reservoir in two sub-populations of people living with HIV: treatment-naïve adults (Population 1) and…
- Trial name
- ENTRANCE (NCT07053384)
- Testing
- VH3810109, Fostemsavir (FTR), SOC INSTI-based ART
- Where
- 41 sites in United States, Belgium and 4 more
- Volunteers
- 107 people
- Sponsor
- ViiV Healthcare
HIV Infections
A Pharmacokinetic Study of Dapivirine Vaginal Rings in Belgium
IPM 018 is a double-blind, randomized, placebo-controlled study conducted at one site in Belgium among 24 healthy, HIV-negative women to evaluate dapivirine release for 28 days from matrix and reservoir intravaginal rings, each…
- Trial name
- NCT00469768
- Testing
- dapivirine reservoir intravaginal ring, dapivirine matrix intravaginal ring
- Where
- Belgium
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- International Partnership for Microbicides, Inc.
Hiv
Analysis of the Reservoir in Individuals Controlling HIV Infection
The aim of this study is the gain new insights into HIV latency in HIV controllers through extensive blood an tissue sampling (lymph node, colon biopsies, placenta) from 25 individuals living with HIV and healthy individuals.
- Trial name
- ARCH (NCT06016114)
- Testing
- HIV Latency Diagnostic Sampling
- Volunteers
- 25 people
- Sponsor
- University Hospital, Ghent
Chronic HIV Infections
Chidamide in Combination With Antiretroviral Therapy for Eradication of the Latent HIV-1 Reservoir
HIV replication can be effectively suppressed and acquired immunodeficiency syndrome(AIDS) can be prevented with highly active antiretroviral therapy (HAART).
- Trial name
- CHARTER (NCT02513901)
- Testing
- Chidamide
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Tang-Du Hospital
HIV-1-infection
LRAs United as a Novel Anti-HIV Strategy.
A translational proof of concept study in humans on the primary research question whether novel anti-human immunodeficiency virus (HIV) latency strategies, including a BAF inhibitor and a histone deacetylase inhibitor, result in…
- Trial name
- LUNA (NCT03525730)
- Testing
- Valproic Acid, Pyrimethamine
- Where
- Netherlands
- Volunteers
- 28 people
- Sponsor
- Erasmus Medical Center
HIV-1 Infections
Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women
Raltegravir not only has a unique mechanism of action, but may also have other unique effects on suppression of viral replication, viral reservoir, and immune reconstitution in blood and other important compartments.
- Trial name
- ICE-002 (NCT00984152)
- Testing
- TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily, TDF/FTC + Efavirenz (Atripla) Once-Daily
- Where
- 5 sites in United States
- Sponsor
- Rush University Medical Center
HIV, HIV-associated Neurocognitive Disorder (HAND)
Identification and Quantification of HIV CNS Latency Biomarkers
Human Immunodeficiency Virus (HIV) remains in infected patients receiving highly active antiretroviral therapy (HAART) for many years.
- Trial name
- NCT02989285
- Where
- Australia
- Volunteers
- 70 people
- Sponsor
- St Vincent's Hospital, Sydney
HIV-1-infection
HIV Persistence in Lymph Node and Peripheral Blood
The aim of this project is to determine whether latent HIV is enriched in cells expressing certain proteins (receptors) on their surface and whether it is possible to eliminate these cells through the use of drugs that…
- Trial name
- HIV-PRADA (NCT03426189)
- Testing
- Leukapheresis, Lymph node biopsy
- Where
- Australia
- Volunteers
- 8 people
- Sponsor
- University of Melbourne
HIV, HIV Infections
The Tatelo Plus Study
The purpose of this study is to advance pediatric HIV treatment and cure research by evaluating the impact of a combination of three anti-HIV-1 broadly neutralizing antibodies (bNAbs) or analytic treatment interruption (ATI) on…
- Trial name
- NCT06508749
- Testing
- PGDM1400LS, VRC07-523LS, PGT121.414.LS
- Where
- 2 sites in Botswana
- Volunteers
- 41 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV
Research In Viral Eradication of HIV Reservoirs
This study will be a two-arm prospective 1:1 randomised controlled trial comparing: Arm A: cART preferably including raltegravir (combination ART cART - control) Arm B: cART preferably including raltegravir (cART) plus…
- Trial name
- RIVER (NCT02336074)
- Testing
- Combination Antiretroviral Therapy (cART), Raltegravir, Vorinostat
- Where
- 6 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- Imperial College London
Chronic HIV Infections
Chidamide in Combination With ART for Reactivation of the Latent HIV-1 Reservoir
HIV replication can be effectively suppressed and acquired immunodeficiency syndrome(AIDS) can be prevented with highly active antiretroviral therapy (HAART).
- Trial name
- NCT02902185
- Testing
- ART plus Chidamide
- Where
- 3 sites in China
- Volunteers
- 60 people
- Sponsor
- Tang-Du Hospital
Acute HIV Infection, HIV CNS Involvement
Using Telmisartan With ART During Acute HIV Infection to Reduce the CNS Reservoirs of HIV and Lymph Node Fibrosis
Primary objective: To compare telmisartan therapy + antiretroviral therapy (ART) versus ART alone during acute Human Immunodeficiency Virus (HIV)a infection in reducing systemic immune activation and trafficking of activated and…
- Trial name
- NCT02750059
- Testing
- TDF/3TC/EFV + Telmisartan, TDF/3TC/EFV only
- Where
- Thailand
- Volunteers
- 21 people
- Sponsor
- SEARCH Research Foundation
HIV Infection
Bryostatin-1 Effect on HIV-1 Latency and Reservoir in HIV-1 Infected Patients Receiving Antiretroviral Treatment
Phase I, randomized, double blind, placebo-controlled, dose-finding trial. The trial´s goal is to evaluate two different doses of Bryostatin on HIV-1 latency and reservoir in HIV-1 infected patients receiving antiretroviral…
- Trial name
- BRYOLAT (NCT02269605)
- Testing
- Bryostatin 1 (10ug/m2), Bryostatin 1 (20ug/m2)
- Where
- Spain
- Volunteers
- 12 people
- Sponsor
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
HIV-1-infection
Implication for Strategies of Long Term Control of Viral Replication in Patient With Primary HIV Infection (PHI).
Multicenter, parallel group, randomised, open label, study. Twenty-five clinical centers constituting the InAction network will participate the study.
- Trial name
- P25-INACTION (NCT04225325)
- Testing
- SYMTUZA, DESCOVY+DOLUTEGRAVIR, SYMTUZA+DOLUTEGRAVIR
- Where
- Italy
- Volunteers
- 112 people
- Sponsor
- ADRIANO LAZZARIN, MD